GlassScriptPhysician profile
Brian C Reed
NPI 1538432190
$9,397.22
in general payments reported to CMS, 2019-2025
30 companies · $3,471 in 2025
The $3,471 reported for 2025 was more than what 82% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $203 · 2020: $135 · 2021: $144 · 2022: $762 · 2023: $1,588 · 2024: $3,093 · 2025: $3,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,896 · Education: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,895.96 |
| Education | $256.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,849.55 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $1,701.50 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,063.70 | 2020-2025 | |
| Grifols USA, LLC | $841.55 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Glaxosmithkline, LLC. | $492.04 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $393.15 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Amgen INC. | $334.83 | 2023-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $322.48 | 2022-2025 | Takhzyro, Hyqvia, Cuvitru |
| Genentech USA, INC. | $316.50 | 2023-2025 | Xolair |
| Pharming Healthcare, INC. | $315.80 | 2023-2025 | Ruconest |
| Optinose US, INC. | $267.40 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $262.87 | 2024-2025 | |
| Pfizer INC. | $227.94 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $151.98 | 2023-2025 | |
| Incyte Corporation | $121.61 | 2024-2025 | Opzelura |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $111.74 | 2024-2025 | Sajazir |
| Biocryst US Sales Co., LLC | $80.80 | 2023-2024 | Orladeyo |
| Alk-Abello, INC | $72.97 | 2019 | |
| Verona Pharma, INC. | $71.43 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $68.33 | 2024-2025 | Zemaira |
| Abbvie INC. | $60.34 | 2024 | |
| Lilly USA, LLC | $44.63 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $41.47 | 2023-2025 | Ryaltris |
| Blueprint Medicines Corporation | $38.98 | 2023-2024 | Ayvakit |
| Organon LLC | $32.29 | 2025 | Vtama |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Greer Laboratories, INC. | $25.50 | 2019 | |
| Ionis Pharmaceuticals, INC. | $23.06 | 2025 | Dawnzera |
| Smith+Nephew, INC. | $19.42 | 2020 | |
| Paratek Pharmaceuticals, INC. | $16.12 | 2025 | Xhance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.